

Hong Kong Society of Uro-Oncology

URO-ONCOLOGY

ASIA 2022

VIRTUAL MEETING
on 22-23 January 2022

WEBSITE



EXPLORE MORE

REGISTRATION



REGISTER NOW!



Prof. Andrea Necchi
Associate Professor,
Vita-Salute San Raffaele University,
Head of Genitourinary Medical Oncology,
IRCCS San Raffaele Hospital and
Scientific Institute, Milan, Italy



Prof. Andrew Armstrong
Professor of Medicine, Surgery,
Pharmacology and Cancer Biology,
Director of Research, the Duke Cancer Institute Center
for Prostate and Urologic Cancers,
Divisions of Medical Oncology and Urology,
Duke University, United States




Prof. Ashish M. Kamat
Professor, Department of Urology,
Division of Surgery,
The University of Texas MD Anderson Cancer Center,
Houston, Texas, United States



Prof. Bertrand Tombal
Chairman, Department of Surgery,
Cliniques Universitaires Saint Luc,
Université Catholique de Louvain,
Belgium



Dr. Hans Hammers
Associate Professor, Internal Medicine,
Eugene P. Frenkel, M.D. Scholar in Clinical Medicine,
Division of Hematology-Oncology,
The University of Texas Southwestern Medical Center,
United States



Dr. Joaquin Mateo
Group Leader,
Prostate Cancer Translational Research Group,
Vall d'Hebron Institute of Oncology,
Medical Oncologist, GU Cancers Division,
Vall d'Hebron University Hospital, Barcelona, Spain



Prof. Joe O'Sullivan
Clinical Professor, School of Medicine,
Dentistry and Biomedical Sciences,
Patrick G Johnston Centre for Cancer Research,
Queen's University Belfast, United Kingdom



Prof. Kim Nguyen Chi
Medical Oncologist, Vancouver Cancer Centre
and Vancouver Prostate Centre, Chief Medical Officer, BC Cancer,
Professor, Faculty of Medicine, University of British Columbia,
Professor, Faculty of Health Sciences,
Simon Fraser University, Canada



Associate Prof. Peter Chiu
Associate Professor,
SH Ho Urology Centre, Department of Surgery,
The Chinese University of Hong Kong,
Honorary Secretary, Hong Kong Urological Association



Prof. Piet Ost
Associate Professor,
Faculty of Medicine and Health Sciences,
Ghent University, Belgium



Prof. Ricardo A Rendon
Professor, Department of Urology,
Faculty of Medicine,
Dalhousie University, Canada



Prof. Sumanta Kumar Pal
Professor, Department of Medical Oncology,
City of Hope Comprehensive Cancer Center,
United States

URO-ONCOLOGY ASIA 2022

AGENDA

22nd January 2022 (Saturday)

HK Time (GMT+8)

Topics

Speakers

Chairmen

13:25-13:30

Welcoming Speech

Dr. Philip Kwong

President of Hong Kong Society of Uro-Oncology,
Hong Kong

SESSION 1 (PROSTATE SESSION)

13:30-14:00

Lecture 1: Genomic testing in advanced prostate cancer

Associate Prof. Peter Chiu

Associate Professor,
SH Ho Urology Centre, Department of Surgery,
The Chinese University of Hong Kong,
Honorary Secretary, Hong Kong Urological Association

Dr. Martin Lam

Associate Consultant,
Department of Oncology,
United Christian Hospital, Hong Kong,
Council Member, Hong Kong Society of Uro-Oncology

14:00-14:30

Lecture 2: Understanding the role of PSMA targeting agents in the management of advanced prostate cancer

Prof. Joe O'Sullivan

Clinical Professor, School of Medicine,
Dentistry and Biomedical Sciences,
Patrick G Johnston Centre for Cancer Research,
Queen's University Belfast, United Kingdom

Dr. Ma Wai Kit

Specialist in Urology,
Honorary Clinical Associate Professor,
The University of Hong Kong,
Council Member, Hong Kong Urological Association

14:30-15:00

Lecture 3: Metastasis-directed therapy for oligometastasis

Prof. Piet Ost

Associate Professor, Faculty of Medicine and Health Sciences, Ghent University, Belgium

Dr. Law Ka Suet

Associate Consultant, Department of Oncology,
Princess Margaret Hospital, Hong Kong,
Council Member, Hong Kong Society of Uro-Oncology

15:00-15:30

Lecture 4: Evolving CRPC management with proven agents and emerging options

Prof. Bertrand Tombal

Chairman, Department of Surgery,
Cliniques Universitaires Saint Luc,
Université Catholique de Louvain, Belgium

Dr. Peter Chiu

Associate Professor, Department of Surgery,
The Chinese University of Hong Kong,
Honorary Secretary, Hong Kong Urological Association

15:30-15:50

Panel discussion and Q&A

15:50-16:00

BREAK

SESSION 2 (UROTHELIAL CA SESSION)

16:00-16:30

Lecture 5: Managing the sequential therapeutic options in advanced urothelial carcinoma

Prof. Andrea Necchi

Associate Professor, Vita-Salute San Raffaele University,
Head of Genitourinary Medical Oncology,
IRCCS San Raffaele Hospital and Scientific Institute,
Milan, Italy

Dr. Daisy Lam

Consultant, Department of Clinical Oncology,
Prince of Wales Hospital, Hong Kong,
Council Member, Hong Kong Society of Uro-Oncology

16:30-17:00

Lecture 6: Novel treatment for non-muscle invasive bladder cancer

Dr. Ashish M. Kamat

Professor, Department of Urology, Division of Surgery,
The University of Texas MD Anderson Cancer Center,
Houston, Texas, United States

Dr. Samuel Yee

Consultant, Division of Urology,
Department of Surgery,
Prince of Wales Hospital, Hong Kong,
Council Member, Hong Kong Urological Association

17:00-17:20

Panel discussion and Q&A

17:20-17:30

Closing of day 1

URO-ONCOLOGY ASIA 2022

AGENDA

23rd January 2022 (Sunday)

HK Time (GMT+8)

Topics

Speakers

Chairmen

SESSION 3 (PROSTATE SESSION)

09:00-09:30

Lecture 7: Liquid biopsy for guiding precision medicine in advanced prostate cancer

Dr. Joaquin Mateo

Group Leader,
Prostate Cancer Translational Research Group,
Vall d'Hebron Institute of Oncology, Medical Oncologist,
GU Cancers Division, Vall d'Hebron University Hospital,
Barcelona, Spain

Dr. Tim Chan

Associate Consultant, Department of Clinical Oncology,
Queen Elizabeth Hospital, Hong Kong,
Council Member, Hong Kong Society of Uro-Oncology

09:30-10:00

Lecture 8: The evolving landscape of mHSPC:
The latest perspective

Prof. Andrew Armstrong

Professor of Medicine, Surgery,
Pharmacology and Cancer Biology,
Director of Research, the Duke Cancer Institute Center
for Prostate and Urologic Cancers, Divisions of
Medical Oncology and Urology, Duke University,
United States

Dr. Clarence Leung

Associate Consultant, Division of Urology,
Department of Surgery, Kwong Wah Hospital,
Hong Kong,
Council Member, Hong Kong Urological Association

10:00-10:30

Lecture 9: Changing landscape in mHSPC

Prof. Kim Nguyen Chi

Medical Oncologist, Vancouver Cancer Centre and
Vancouver Prostate Centre, Chief Medical Officer, BC Cancer,
Professor, Faculty of Medicine, University of British Columbia,
Professor, Faculty of Health Sciences, Simon Fraser University,
Canada

Dr. Angus Leung

Clinical Oncologist,
Clinical Associate Professor (Honorary),
Department of Medicine and Therapeutics,
The Chinese University of Hong Kong,
Honorary Treasurer, Hong Kong Society of
Uro-Oncology

10:30-11:00

Lecture 10: Optimizing ADT in PCa with CVD
history: Real-world evidence & mitigation
strategy

Prof. Ricardo A Rendon

Professor, Department of Urology, Faculty of Medicine,
Dalhousie University, Canada

Dr. Raymond Kan

Associate Consultant, Division of Urology,
Department of Surgery, Queen Elizabeth Hospital,
Hong Kong,
Honorary Treasurer, Hong Kong Urological Association

11:00-11:20

Panel discussion and Q&A

SESSION 4 (RCC SESSION)

11:20-11:50

Lecture 11: The evolving treatment landscape:
Optimizing frontline strategy in advanced RCC

Prof. Sumanta Kumar Pal

Professor, Department of Medical Oncology,
City of Hope Comprehensive Cancer Center, United States

Dr. Darren Poon

Honorary Consultant, Clinical Oncology,
Hong Kong Sanatorium & Hospital, Hong Kong,
Honorary Clinical Associate Professor,
The Chinese University of Hong Kong,
Vice President, Hong Kong Society of Uro-Oncology

11:50-12:20

Lecture 12: Dual immune checkpoint blockade
in the treatment of advanced RCC

Dr. Hans Hammers

Associate Professor, Internal Medicine,
Eugene P. Frenkel, M.D. Scholar in Clinical Medicine,
Division of Hematology-Oncology,
The University of Texas Southwestern Medical Center,
United States

Associate Prof. Ravindran Kanesvaran

Deputy Head and Senior Consultant, Division of
Medical Oncology, National Cancer Centre Singapore

12:20-12:40

Panel discussion and Q&A

12:40-12:45

Closing Speech

Dr. Darren Poon

Vice-President of Hong Kong Society of Uro-Oncology,
Hong Kong